Yi, Qing

Publications

Sort by

Co-Author Network

selected publications

A guideline on the molecular ecosystem regulating ferroptosis. Nature cell biology. 2024 Review GET IT
Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers. Journal for immunotherapy of cancer. 2024 Academic Article GET IT
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 Academic Article GET IT
Lipid peroxidation of immune cells in cancer. Frontiers in immunology. 2024 Review GET IT
Isolation of adoptively transferred CD8⁺ T cells in mouse tumor tissues for lipid peroxidation detection. STAR protocols. 2022 Academic Article GET IT
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors. Journal of hematology & oncology. 2022 Letter GET IT
Times cited: 2
IL-9/STAT3/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity. The Journal of clinical investigation. 2022 Academic Article GET IT
Times cited: 35
Correction: Enhanced Lipid Accumulation and Metabolism Are Required for the Differentiation and Activation of Tumor-Associated Macrophages. 2022 GET IT
Times cited: 2
ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1. Blood. 2022 Academic Article GET IT
Times cited: 5
ALCAM regulates multiple myeloma chemoresistant side population. Cell death & disease. 2022 Academic Article GET IT
Times cited: 5
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet. Haematology. 2022 Review GET IT
Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice. Science translational medicine. 2022 Academic Article GET IT
Times cited: 4
RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 2022 Academic Article GET IT
Times cited: 5
ALCAM-EGFR interaction regulates myelomagenesis. Blood advances. 2021 Academic Article GET IT
Times cited: 8
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells. Cancer cell. 2021 Academic Article GET IT
Times cited: 24
BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions. Cell death & disease. 2021 Academic Article GET IT
Times cited: 14
CD36-mediated ferroptosis dampens intratumoral CD8⁺ T cell effector function and impairs their antitumor ability. Cell metabolism. 2021 Academic Article GET IT
Times cited: 333
Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma. Haematologica. 2021 Academic Article GET IT
Times cited: 7
Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell metabolism. 2021 Academic Article GET IT
Times cited: 53
MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood. 2020 Academic Article GET IT
Times cited: 30
Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nature communications. 2020 Academic Article GET IT
Times cited: 50
Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. British journal of haematology. 2020 Academic Article GET IT
Times cited: 5
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nature communications. 2020 Academic Article GET IT
Times cited: 93
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer research. 2020 Academic Article GET IT
Times cited: 30
Enhanced Lipid Accumulation and Metabolism Are Required for the Differentiation and Activation of Tumor-Associated Macrophages. Cancer research. 2020 Academic Article GET IT
Times cited: 213
The many substrates and functions of NEDD4-1. Cell death & disease. 2019 Review GET IT
Times cited: 62
CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma. Cell death & disease. 2019 Academic Article GET IT
Times cited: 36
Cholesterol induces T cell exhaustion. Aging. 2019 Editorial Article GET IT
Times cited: 7
The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma. International journal of cancer. 2019 Academic Article GET IT
Times cited: 23
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Science translational medicine. 2019 Academic Article GET IT
Times cited: 71
Cholesterol Induces CD8⁺ T Cell Exhaustion in the Tumor Microenvironment. Cell metabolism. 2019 Academic Article GET IT
Times cited: 456
TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways. Journal for immunotherapy of cancer. 2019 Academic Article GET IT
Times cited: 42
Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. Cancer letters. 2019 Academic Article GET IT
Times cited: 32
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. Cancer letters. 2018 Academic Article GET IT
Times cited: 9
E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 27
IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells. Cellular & molecular immunology. 2018 Academic Article GET IT
Times cited: 23
Interleukin-33 Contributes to the Induction of Th9 Cells and Antitumor Efficacy by Dectin-1-Activated Dendritic Cells. Frontiers in immunology. 2018 Academic Article GET IT
Times cited: 30
MicroRNA-31-5p enhances the Warburg effect via targeting FIH. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2018 Academic Article GET IT
Times cited: 36
Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. 2018 GET IT
Times cited: 4
Th9 Cells Represent a Unique Subset of CD4⁺ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer cell. 2018 Academic Article GET IT
Times cited: 106
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease. Haematologica. 2018 Academic Article GET IT
Times cited: 24
Cholesterol negatively regulates IL-9-producing CD8⁺ T cell differentiation and antitumor activity. The Journal of experimental medicine. 2018 Academic Article GET IT
Times cited: 92
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. Journal of hematology & oncology. 2018 Academic Article GET IT
Times cited: 99
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 2018 Academic Article GET IT
Times cited: 107
Dectin-1 stimulates IL-33 expression in dendritic cells via upregulation of IRF4. Laboratory investigation; a journal of technical methods and pathology. 2018 Academic Article GET IT
Times cited: 5
C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis. Science signaling. 2017 Academic Article GET IT
Times cited: 25
BAFF is involved in macrophage-induced bortezomib resistance in myeloma. Cell death & disease. 2017 Academic Article GET IT
Times cited: 19
Foxo1 and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of T_H9 cells programmed by IL-7. Science signaling. 2017 Academic Article GET IT
Times cited: 44
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell research. 2017 Academic Article GET IT
Times cited: 223
Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. Leukemia. 2017 Academic Article GET IT
Times cited: 58
Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1. Oncotarget. 2017 Academic Article GET IT
Times cited: 19
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 45
IL-15 enhances the antitumor effect of human antigen-specific CD8⁺ T cells by cellular senescence delay. Oncoimmunology. 2016 Academic Article GET IT
Times cited: 15
Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy. Oncoimmunology. 2016 Academic Article GET IT
Times cited: 10
ORP4L is essential for T-cell acute lymphoblastic leukemia cell survival. Nature communications. 2016 Academic Article GET IT
Times cited: 55
Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. Nature communications. 2016 Academic Article GET IT
Times cited: 88
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 37
Could B7-H4 serve as a target to activate anti-cancer immunity?. International immunopharmacology. 2016 Review GET IT
Times cited: 15
CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget. 2015 Academic Article GET IT
Times cited: 10
Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma. Oncotarget. 2015 Academic Article GET IT
Times cited: 61
Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B. Hepatology (Baltimore, Md.). 2015 Academic Article GET IT
Times cited: 63
Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget. 2015 Academic Article GET IT
Times cited: 23
Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. The Journal of pathology. 2015 Academic Article GET IT
Times cited: 27
Oxysterol-binding protein-related protein 8 (ORP8) increases sensitivity of hepatocellular carcinoma cells to Fas-mediated apoptosis. The Journal of biological chemistry. 2015 Academic Article GET IT
Times cited: 35
Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-γ and CD40 ligand in vitro. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2014 Academic Article GET IT
Times cited: 31
Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 2014 Academic Article GET IT
Times cited: 58
PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice. Diabetes. 2014 Academic Article GET IT
Times cited: 19
PLK1 and β-TrCP-dependent ubiquitination and degradation of Rap1GAP controls cell proliferation. PloS one. 2014 Academic Article GET IT
Times cited: 8
Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer letters. 2014 Academic Article GET IT
Times cited: 52
A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood. 2014 Academic Article GET IT
Times cited: 80
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway. Cancer biology & therapy. 2014 Academic Article GET IT
Times cited: 21
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nature communications. 2014 Academic Article GET IT
Times cited: 44
USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Molecular cancer. 2014 Academic Article GET IT
Times cited: 31
Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature medicine. 2014 Academic Article GET IT
Times cited: 189
Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer immunology, immunotherapy : CII. 2014 Academic Article GET IT
Times cited: 35
p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. International journal of cancer. 2014 Academic Article GET IT
Times cited: 42
Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma. British journal of haematology. 2014 Academic Article GET IT
Times cited: 29
Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy. Oncoimmunology. 2014 Academic Article GET IT
Times cited: 29
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. International journal of cancer. 2014 Academic Article GET IT
Times cited: 7
Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 99
Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Molecular oncology. 2013 Academic Article GET IT
Times cited: 215
Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PloS one. 2013 Academic Article GET IT
Times cited: 13
In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Molecular cancer therapeutics. 2013 Academic Article GET IT
Times cited: 20
Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia. 2013 Academic Article GET IT
Times cited: 47
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica. 2013 Academic Article GET IT
Times cited: 55
Utilizing T_H9 cells as a novel therapeutic strategy for malignancies. Oncoimmunology. 2013 Academic Article GET IT
Times cited: 15
Immunotherapy for multiple myeloma. Clinical & developmental immunology. 2012 Editorial Article GET IT
Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nature genetics. 2012 Academic Article GET IT
Times cited: 264
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clinical and experimental immunology. 2012 Academic Article GET IT
Times cited: 37
Th9 cells promote antitumor immune responses in vivo. The Journal of clinical investigation. 2012 Academic Article GET IT
Times cited: 266
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer research. 2012 Academic Article GET IT
Times cited: 62
PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2012 Academic Article GET IT
Times cited: 121
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Academic Article GET IT
Times cited: 92
Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer. 2012 Academic Article GET IT
Times cited: 43
DKK1 as a novel target for myeloma immunotherapy. Oncoimmunology. 2012 Academic Article GET IT
Times cited: 10
Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma. Hepatology (Baltimore, Md.). 2012 Academic Article GET IT
Times cited: 45
HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas. Gut. 2012 Academic Article GET IT
Times cited: 30
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia. 2012 Academic Article GET IT
Times cited: 23
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. Journal of molecular medicine (Berlin, Germany). 2011 Academic Article GET IT
Times cited: 52
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood. 2011 Academic Article GET IT
Times cited: 64
CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer immunology, immunotherapy : CII. 2011 Academic Article GET IT
Times cited: 21
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leukemia research. 2011 Academic Article GET IT
Times cited: 5
Strategic consideration on treatment of multiple myeloma. Chinese medical journal. 2011 Editorial Article GET IT
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 5
Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. American journal of blood research. 2011 Academic Article GET IT
American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation. American journal of blood research. 2011 Academic Article GET IT
Launching of american journal of blood research. American journal of blood research. 2011 Academic Article GET IT
Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. British journal of haematology. 2011 Academic Article GET IT
Times cited: 9
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica. 2011 Academic Article GET IT
Times cited: 44
Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer biology & therapy. 2011 Academic Article GET IT
Times cited: 32
Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia research. 2010 Academic Article GET IT
Times cited: 56
IL-2 mRNA stabilization upon PMA stimulation is dependent on NF90-Ser647 phosphorylation by protein kinase CbetaI. Journal of immunology (Baltimore, Md. : 1950). 2010 Academic Article GET IT
Times cited: 36
Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010 Academic Article GET IT
Times cited: 42
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. British journal of haematology. 2010 Academic Article GET IT
Times cited: 60
Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer. 2010 Review GET IT
Times cited: 28
Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood. 2010 Academic Article GET IT
Times cited: 182
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. American journal of hematology. 2009 Academic Article GET IT
Times cited: 133
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009 Academic Article GET IT
Times cited: 251
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009 Academic Article GET IT
Times cited: 29
Multiple myeloma, painful neuropathy, acupuncture?. American journal of clinical oncology. 2009 Review GET IT
Times cited: 20
Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009 Academic Article GET IT
Times cited: 27
Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 16
Novel immunotherapies. Cancer journal (Sudbury, Mass.). 2009 Review GET IT
Times cited: 23
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer research. 2008 Academic Article GET IT
Times cited: 59
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008 Academic Article GET IT
Times cited: 214
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 25
Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. American journal of hematology. 2008 Review GET IT
Times cited: 19
Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation. Journal of immunology (Baltimore, Md. : 1950). 2008 Academic Article GET IT
Times cited: 62
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2007 Academic Article GET IT
Times cited: 81
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer cell. 2007 Academic Article GET IT
Times cited: 99
Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007 Academic Article GET IT
Times cited: 48
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Academic Article GET IT
Times cited: 110
Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Frontiers in bioscience : a journal and virtual library. 2007 Academic Article GET IT
Times cited: 23
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007 Academic Article GET IT
Times cited: 49
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer cell. 2006 Academic Article GET IT
Times cited: 79
Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood. 2006 Academic Article GET IT
Times cited: 79
Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 49
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood. 2005 Academic Article GET IT
Times cited: 90
Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Experimental hematology. 2005 Academic Article GET IT
Times cited: 76
Monocyte-derived dendritic cells: a promising armament for immunotherapy in human malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Editorial Article GET IT
Times cited: 2
Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer research. 2004 Academic Article GET IT
Times cited: 169
The autoimmune T and B cell repertoires in monozygotic twins discordant for myasthenia gravis. Journal of neuroimmunology. 2004 Academic Article GET IT
Times cited: 13
Dendritic cell-based immunotherapy in multiple myeloma. Leukemia & lymphoma. 2003 Review GET IT
Times cited: 17
Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. Journal of immunology (Baltimore, Md. : 1950). 2003 Academic Article GET IT
Times cited: 56
Immunotherapy in multiple myeloma: current strategies and future prospects. Expert review of vaccines. 2003 Review GET IT
Times cited: 16
Beta2-microglobulin as a potential initiator of inflammatory responses. Trends in immunology. 2003 Letter GET IT
Times cited: 30
Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003 Academic Article GET IT
Times cited: 89
Beta(2)-microglobulin as a negative growth regulator of myeloma cells. British journal of haematology. 2002 Academic Article GET IT
Times cited: 28
Optimizing dendritic cell-based immunotherapy in multiple myeloma. British journal of haematology. 2002 Academic Article GET IT
Times cited: 98
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002 Academic Article GET IT
Times cited: 128
Interleukin-10 gene promoter polymorphisms in multiple myeloma. International journal of cancer. 2001 Academic Article GET IT
Times cited: 52
Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood. 2001 Academic Article GET IT
Times cited: 116
Telomerase activity in plasma cell dyscrasias. British journal of cancer. 2001 Academic Article GET IT
Times cited: 56
Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway. British journal of haematology. 2001 Academic Article GET IT
Times cited: 20
Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. British journal of haematology. 2001 Academic Article GET IT
Times cited: 40
Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. British journal of haematology. 2000 Academic Article GET IT
Times cited: 83
T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. 1999 GET IT
Times cited: 48
Cytokine production from colonic T cells in patients with ulcerative colitis with and without primary sclerosing cholangitis. Diseases of the colon and rectum. 1998 Academic Article GET IT
Times cited: 9
Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer immunology, immunotherapy : CII. 1998 Academic Article GET IT
Times cited: 96
Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8). Blood. 1998 Academic Article GET IT
Times cited: 47
Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood. 1998 Academic Article GET IT
Times cited: 185
Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. British journal of haematology. 1998 Academic Article GET IT
Times cited: 47
Generation of dendritic cells from peripheral blood adherent cells in medium with human serum. Scandinavian journal of immunology. 1998 Academic Article GET IT
Times cited: 45
Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood. 1997 Academic Article GET IT
Times cited: 61
T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden. European journal of immunology. 1997 Academic Article GET IT
Times cited: 62
Current and future therapies for myasthenia gravis. Drugs & aging. 1997 Review GET IT
Times cited: 2
Decreased beta2-adrenergic receptor density on peripheral blood mononuclear cells in myasthenia gravis. Journal of autoimmunity. 1997 Academic Article GET IT
Times cited: 11
The effect of thymectomy on autoreactive T- and B-lymphocytes in myasthenia gravis. Journal of neuroimmunology. 1997 Academic Article GET IT
Times cited: 12
Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. British journal of haematology. 1997 Academic Article GET IT
Times cited: 58
Anti-idiotypic T cells in early stages of myasthenia gravis: increase in the number and prevalence correlated to clinical improvement in patients. Scandinavian journal of immunology. 1996 Academic Article GET IT
Times cited: 1
Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clinical and experimental immunology. 1996 Academic Article GET IT
Times cited: 26
Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?. Medical oncology (Northwood, London, England). 1996 Review GET IT
Times cited: 32
Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. British journal of haematology. 1996 Academic Article GET IT
Times cited: 99
Presynaptic membrane receptor-reactive T lymphocytes in myasthenia gravis. Scandinavian journal of immunology. 1996 Academic Article GET IT
Times cited: 4
T and B lymphocytes reacting with the extracellular loop of the beta 2-adrenergic receptor (beta 2AR) are present in the peripheral blood of patients with myasthenia gravis. Clinical and experimental immunology. 1996 Academic Article GET IT
Times cited: 11
Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood. 1995 Academic Article GET IT
Times cited: 122
Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. British journal of haematology. 1995 Academic Article GET IT
Times cited: 71
Idiotype- and anti-idiotype-reactive T lymphocytes in myasthenia gravis. Evidence for the involvement of different subpopulations of T helper lymphocytes. Journal of immunology (Baltimore, Md. : 1950). 1994 Academic Article GET IT
Times cited: 20
Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. 1994 GET IT
Times cited: 67
Anti-idiotypic B lymphocytes in patients with monoclonal gammopathies. Scandinavian journal of immunology. 1994 Academic Article GET IT
Times cited: 18
Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells. Journal of neuroimmunology. 1994 Academic Article GET IT
Times cited: 55
T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scandinavian journal of immunology. 1993 Academic Article GET IT
Times cited: 49
Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD4 monoclonal antibody. 1993 GET IT
Times cited: 14
Human muscle acetylcholine receptor reactive T and B lymphocytes in myasthenia gravis. Annals of the New York Academy of Sciences. 1993 Academic Article GET IT
Times cited: 1
Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. Journal of neuroimmunology. 1993 Academic Article GET IT
Times cited: 41
Idiotypic and antiidiotypic T and B lymphocytes in myasthenia gravis. Journal of immunology (Baltimore, Md. : 1950). 1992 Academic Article GET IT
Times cited: 14
T-cell epitopes on the human acetylcholine receptor alpha-subunit residues 10-84 in myasthenia gravis. Scandinavian journal of immunology. 1992 Academic Article GET IT
Times cited: 6
Levels of CD5+ B lymphocytes do not differ between patients with myasthenia gravis and healthy individuals. Neurology. 1992 Academic Article GET IT
Times cited: 12
T cells with specificity for idiotypic determinants on human monoclonal autoantibodies in myasthenia gravis. Research in immunology. 1992 Academic Article GET IT
Times cited: 10
Anti-idiotypic immunity as a potential regulator in myeloma and related diseases. Annals of the New York Academy of Sciences. 1991 Review GET IT
Times cited: 14

more ...

less ...

Background

education and training

M.B., Jiangxi Medical College (China) 83
Ph.D., Karolinska Institute (Sweden) 1993
M.Med., Sun Yat-Sen University of Medical Sciences (China) 1986

Contact

full name

Qing Yi

VIVO Weill Cornell Medical College

Qing Yi Professor of Cancer Biology in Medicine

Publications

selected publications

Background

education and training

Contact

full name